INMB241115P2500
- 0.00
- 0.000.00%
INmune Bio Newsroom
Earnings Call: INmune Bio Q3 2024 Results Show Progress in Clinical Trials
BTIG Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $21
Scotiabank Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22
INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript Summary
INmune Bio GAAP EPS of -$0.60 Misses by $0.10
INmune Bio | 10-Q: Q3 2024 Earnings Report
Express News | INmune Bio Q3 Operating Income USD -12.286 Million
Press Release: INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
INmune Bio 3Q Loss/Shr 60c >INMB
Here Are the Major Earnings After the Close Today
INmune Bio Q3 2024 Earnings Preview
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
Earnings Preview: INmune Bio to Report Financial Results Post-market on October 31
Highbridge Capital Management's Strategic Acquisition of INmune Bio Inc Shares
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro Promotes Remyelination
Express News | INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
Insider Stock Buying Reaches US$951.2k On INmune Bio
A. G. P. Initiates INmune Bio(INMB.US) With Buy Rating, Announces Target Price $20
Express News | INmune Bio Inc : Alliance Global Partners Initiates Coverage With Buy Rating; Target Price $20
INmune Bio Initiated With a Buy at Alliance Global Partners